Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Italy / NCT06876662
Recruiting Phase 4

A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma

NCT06876662 · tracked via the Priya Life Science Italy tracker
Sponsor
Eli Lilly and Company
Phase
Phase 4
Started
2025-05-20
Last updated
2026-03-02

Condition(s) studied

Chronic Lymphocytic LeukemiaNon-Hodgkin Lymphoma

Investigational drug(s) / intervention(s)

Pirtobrutinib →

Pirtobrutinib: Administered orally.

Study summary

Study J2N-MC-JZ01 (JZ01) is an individual-study appendix (ISA) under master protocol J2N-MC-JZNY, and represents participants from the completed originator study, clinical study LOXO-BTK-18001/J2N-OX-JZNA. Participants in the originator study will have the opportunity to continue their assigned study intervention or continue their follow-up visits by transitioning to this study. This study will evaluate the long-term safety and efficacy of pirtobrutinib.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Are currently enrolled and active in the originator study, LOXO-BTK-18001. A participant is considered active in the study if they are: * receiving study intervention * in the short-term follow-up period, or * in the long-term follow-up period Exclusion Criteria: * Were a participant in the Phase 1b cohort of Study LOXO-BTK-18001

Primary outcome measure(s)

  • Percentage of Participants with a Grade ≥3 treatment-emergent adverse events (TEAEs) — Time from the Date of the First Dose of Study Intervention (Study Day 1) through 30 Days (+ 7-day window) After the Date of the Last Dose of Study Intervention or The First Date Starting a New Anticancer Therapy, whichever is Earlier

Trial sites (36)

FacilityCityRegionStatus
Sylvester Comprehensive Cancer Center Miami Florida Recruiting
Florida Cancer Specialists Sarasota Florida Recruiting
The Emory Clinic Atlanta Georgia Recruiting
Northwestern University Chicago Illinois Recruiting
Dana-Farber Cancer Institute Boston Massachusetts Recruiting
Mayo Clinic- Minnesota Rochester Minnesota Recruiting
University Of Nebraska Medical Center Omaha Nebraska Recruiting
Cayuga Cancer Center Ithaca New York Active Not Recruiting
Northwell Health Lake Success New York Recruiting
Memorial Sloan-Kettering Cancer Center (MSKCC) - New York New York New York Recruiting
Memorial Sloan-Kettering Cancer Center (MSKCC) - New York New York New York Active Not Recruiting
Duke University Medical Center Durham North Carolina Recruiting
Ohio State University Comprehensive Cancer Center Columbus Ohio Recruiting
University of Pennsylvania Hospital Philadelphia Pennsylvania Recruiting
Tennessee Oncology Nashville Tennessee Recruiting
University of Texas MD Anderson Cancer Center Houston Texas Recruiting
Swedish Cancer Institute Seattle Washington Recruiting
Medical College of Wisconsin Milwaukee Wisconsin Recruiting
Flinders Medical Centre Adelaide Australia Recruiting
Peter MacCallum Cancer Centre Melbourne Australia Completed
Linear Clinical Research Victoria Australia Active Not Recruiting
CHU de Nantes - Hotel Dieu Nantes France Recruiting
IRCCS-AOU di Bologna-Policlinico S.Orsola-Malpighi Bologna Italy Completed
Ospedale San Raffaele Milan Italy Recruiting
Nagoya Medical Center Aichi-Ken Japan Active Not Recruiting
National Cancer Center Hospital Cho-ku Japan Completed
National Hospital Organization Kyushu Cancer Center Fukuoka Japan Active Not Recruiting
Tokai University Hospital- Isehara Campus Isehara Japan Active Not Recruiting
Tohoku University Hospital Miyagi-Ken Japan Active Not Recruiting
Hokkaido University Hospital Sapporo Japan Active Not Recruiting
Pratia MCM Krakow Krakow Poland Recruiting
Instytut Hermatologii I Transfuzjologii Warsaw Poland Recruiting
Seoul National University Hospital Seoul South Korea Recruiting
St James's University Hospital Leeds United Kingdom Recruiting
Churchill Hospital Oxford United Kingdom Recruiting
Derriford Hospital Plymouth United Kingdom Recruiting

More Eli Lilly and Company trials in Italy

A Study of Abemaciclib (LY2835219) Combined With Fulvestrant in Women With Hormone Receptor Positive HER2 Negative Breast Cancer Active, not recruiting
A Study of Selpercatinib After Surgery or Radiation in Participants With Non-Small Cell Lung Cancer (NSCLC) Active, not recruiting
A Study of Abemaciclib (LY2835219) Plus Tamoxifen or Abemaciclib Alone in Women With Metastatic Breast Cancer Active, not recruiting
A Study of Eltrekibart and Mirikizumab in Adult Patients With Moderately to Severely Active Ulcerative Colitis Active, not recruiting
Endocrine Therapy With or Without Abemaciclib (LY2835219) Following Surgery in Participants With Breast Cancer Active, not recruiting

Other trials for the same condition

A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL) Recruiting
A Study to Investigate Sonrotoclax Combined With Zanubrutinib Versus Zanubrutinib Alone in Participants With Previously Untreated Chronic Lymphocytic Leukemia Active, not recruiting
Acalabrutinib Real World Italian obSErvational Study -ARISE Active, not recruiting
ACP-196 (Acalabrutinib), a Novel Bruton Tyrosine Kinase (BTK) Inhibitor, for Treatment of Chronic Lymphocytic Leukemia, Richter's Syndrome or Prolymphocytic Leukemia Active, not recruiting
A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06876662 on ClinicalTrials.gov ↗ ← All trials in Italy